Nci sbir plan web seminar: ip strategy

Wednesday, March 27, 2019, 2:00 – 3:30 p.m. Eastern Daylight Time

NCI SBIR PLAN Web seminar series offers NCI SBIR/STTR awardees to discover topics essential for their commercialization efforts from both industry expert and fellow awardees which have effectively went through process. On March 27, the NCI SBIR PLAN Web seminar covers “Building a powerful IP Strategy.”

Attendees will receive a opportunity to:

find out about IP strategy from your SBIR IP Expert
listen to awardees who’ve effectively established IP strategies
inquire towards the expert and awardees
network using the loudspeakers along with other SBIR/STTR awardees

Following the first hour of web seminar, each speaker is going to be open to talk to attendees in a 30-minute breakout session. If you’d like to become assigned a particular breakout session or you have questions regarding the web seminar, please contact Ashim Subedee (ashim.subedee@nih.gov) before the web seminar.

Agenda:

2:00 – 3:00 p.m.

IP 101 for SBIR/STTR companies (J.P. Kim)
Awardee IP Strategy Experience (Gail Sonenshein, Mike Reder)
Open Q&A

3:00 – 3:30 p.m.

Breakout session with panelists

Nci sbir plan web seminar: ip strategy STTR program

Loudspeakers:

J.P. Kim, Program Manager and NIH Extramural Data Discussing Policy Officer, Office of Extramural Programs, National Institutes of Health

Gail Sonenshein, Co-founder and President, Adecto Pharmaceuticals

Mike Reder, Director and Chief executive officer, Celdara Medical

J.P. Kim, J.D., M.B.A., M.Sc., M.A.L.S, Program Manager and NIH Extramural Data Discussing Policy Officer, Office of Extramural Programs, National Institutes of Health

J.P. Kim became a member of the SBIR/STTR program team like a Program Manager and NIH Extramural Data Discussing Policy Officer underneath the Office of Extramural Programs (OEP). J.P. brings over 3 decades of ip experience and NIH experience for everyone as the second source of the NIH small company research community and NIH staff on matters connected using the SBIR/STTR program, in addition to assisting in supplying data management/discussing policy guidance and ip policy guidance as particularly associated with small companies and also the SBIR/STTR programs.

Just before joining the SBIR/STTR team, J.P. offered as Director & Policy Officer from the Division of Extramural Inventions & Technology Sources (DEITR) at work of Insurance policy for Extramural Research Administration (OPERA) underneath the NIH Office of Extramural Research (OER) and offered like a Senior Technology Licensing Specialist & Patent Consultant at work of Technology Transfer (OTT) underneath the NIH Office of Intramural Research (OIR). During the period of twenty years at NIH, his responsibilities incorporated dealing with the extramural community and developing, applying, and supplying policy guidance, oversight, education/training, and day-to-day management on extramural invention reporting, iEdison, and knowledge discussing/management under NIH extramural funding contracts (including under SBIR awards). While underneath the intramural program, J.P. labored around the development and change in inventions as a result of the NIH intramural research program, overseeing patent prosecution of inventions and labored to recognize collaborations along with other possibilities with small companies along with other organizations for out-licensing and additional growth and development of NIH technologies into commercial products to profit the general public health. J.P.’s patenting and licensing efforts led to various products reaching the marketplace that earned royalties well over $$ 30 million yearly.

Wednesday, March 27, 2019, 2:00 – 3:30 p.m. Eastern Daylight Time

Attendees will receive a opportunity to:

find out about IP strategy from your SBIR IP Expert
listen to awardees who’ve effectively established IP strategies
inquire towards the expert and awardees
network using the loudspeakers along with other SBIR/STTR awardees

Agenda:

2:00 – 3:00 p.m.

IP 101 for SBIR/STTR companies (J.P. Kim)
Awardee IP Strategy Experience (Gail Sonenshein, Mike Reder)
Open Q&A

3:00 – 3:30 p.m.

Breakout session with panelists

Loudspeakers:

J.P. Kim, Program Manager and NIH Extramural Data Discussing Policy Officer, Office of Extramural Programs, National Institutes of Health

Gail Sonenshein, Co-founder and President, Adecto Pharmaceuticals

Mike Reder, Director and Chief executive officer, Celdara Medical

J.P. Kim, J.D., M.B.A., M.Sc., M.A.L.S, Program Manager and NIH Extramural Data Discussing Policy Officer, Office of Extramural Programs, National Institutes of Health

J.P. is really a registered U.S. Patent Attorney using the U.S. Patent and Trademark Office (USPTO) underneath the U.S. Department of Commerce, and it is registered to rehearse prior to the Maryland Courts, the U.S. Court of Worldwide Trade (CIT), the U.S. Court of Appeals for that Federal Circuit (CAFC), the U.S. Top Court, along with a couple of other federal courts. He’s over 30 experience dealing with patents along with other ip matters for companies, universities, along with other organizations at lawyers along with the government. J.P. received his J.D., M.B.A. in Worldwide Business and Worldwide Marketing, M.Sc. in Biotechnology, M.P.P. in Health Policy by having an additional certification within the Nonprofit Sector, M.A. in Liberal Studies having a concentrate on Social/Public Policy along with a thesis around the bioethics of human cloning, B.Sc. in Zoology (Chemistry minor), along with a B.A. in Psychology, in addition to further graduate study in Genetics and Sustainability Leadership for any greener world. He earned levels from Georgetown College, George Washington College, American College, the College of Maryland, and Johns Hopkins College.

Gail E. Sonenshein, Ph.D., Co-founder/President, Adecto Pharmaceuticals

Dr. Gail E. Sonenshein is co-Founder and President of Adecto Pharmaceuticals, Corporation. Dr. Sonenshein, who received her Ph.D. in Biology from Durch, is definitely an worldwide recognized expert on oncogenes, transformation and cancer of the breast with more than 175 papers in top-tier journals. She founded and directed the Women’s Health Interdisciplinary Research Center at Boston College Med school and offered around the Board of Scientific Counselors from the NIH NIAID. Her laboratory makes cutting edge breakthroughs around the multiple roles from the NF-κB transcription factor family and also the c-MYC oncogene as well as in transformation, charge of cell cycle, differentiation, and cell survival. This brought towards the identification and validation of several targets for cancer treatment, such as the cell surface protein ADAM8. Particularly, work from her laboratory shown ADAM8 is really a critical driver of breast tumor growth and metastasis. ADAM8 is definitely an independent predictor of poor outcome for patients with Triple-Negative Cancer Of The Breast (TNBC) along with other solid tumors including lung, pancreatic, liver, and stomach, rich in unmet medical need. Adecto Pharmaceuticals, Corporation. (Adecto) is definitely an early-stage cancer therapeutics company, spun removed from Dr. Sonenshein’s lab at Tufts College Med school that’s developing therapies to focus on ADAM8-driven aggressive cancers (established in the finish of 2014). Underneath the aegis of the Phase I STTR grant, a panel of highly specific anti-human ADAM8 mouse monoclonal antibodies (termed ADPs) were generated that hinder the 2 domains crucial for tumor growth and spread, i.e., the Metalloproteinase [MP] and Disintegrin [DI] domains, correspondingly. The very best inhibitors that reduced pre-existing primary TNBC tumor growth and metastasis, and improved survival of rodents as monotherapies (ADP2 and ADP13) were identified. In combinatorial therapy having a Standard-of-Care chemotherapy (CT), ADP2 and ADP13 enhanced CT-mediated tumor inhibition and disease-free and overall survival. Thus, ADAM8 antibody combination therapy could dramatically improve patient outcome. A Methods patent about this technologies have been filed [U.S. 14/940,344 (November. 13, 2015)] along with a Composition of Matter patent around the lead antibodies is within preparation. Adecto, that has negotiated a unique choice to license the ADP antibodies and technology from Tufts College, was lately awarded a Phase II SBIR grant to carry on growth and development of this therapy along with a Phase I SBIR for growth and development of a diagnostic assay. Our development plans follow well-defined regulatory and clinical development pathways established by other oncology biologics and companion diagnostics in the market (e.g., Herceptin and also the Ventana 4B5 monoclonal HER2 antibody for IHC-based recognition of HER2 positive tumors). Presently, there aren’t any treating ADAM8-expressing tumors. Effective completing the suggested Phase II studies will well-position Adecto for future Phase IIb funding and partnership development to create ADAM8 antibody-based therapeutics to patients as rapidly and securely as possible done.

Mike Reder, Ph.D., Director/Chief executive officer, Celdara Medical

Nci sbir plan web seminar: ip strategy Wednesday, March 27

Mike cofounded Celdara Medical and presently works as a Director so that as Chief executive officer. He’d formerly founded the brand new Ventures Office at Dartmouth School Of Medicine but still can serve as its first Director. Just before Dartmouth, Mike brought business development, open innovation, and understanding management initiatives at Cabot Corporation where he offered as part of Cabot’s Research Council, Technology Board, and Nanotechnology EHS Council. Mike became a member of Cabot from PolyTechnos Venture-Partners, a Munich-based investment capital firm. He’s offered on numerous non- as well as for-profit boards, including Virtici, MBV, StemSynergy Therapeutics, NIH’s TREAT Program and also the College of Vermont’s SPARK Program. Mike has testified before Congress on entrepreneurship, was hired through the Governor towards the Nh Innovation Research Center’s Board of Company directors, by US Senator Jeanne Shaheen to her Small Company Advisory Council. Mike earned a b -.Sc. with Top Class Honours in the College of Waterloo, along with a Ph.D. (Chemistry) like a Brown-Wetherill Fellow at Purdue College and Ludwig Maximilians Universität.

Resourse: https://sbir.cancer.gov/node/